{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:40:15Z","timestamp":1767987615995,"version":"3.49.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T00:00:00Z","timestamp":1472688000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virus Research"],"published-print":{"date-parts":[[2016,9]]},"DOI":"10.1016\/j.virusres.2016.07.008","type":"journal-article","created":{"date-parts":[[2016,7,20]],"date-time":"2016-07-20T18:05:33Z","timestamp":1469037933000},"page":"140-146","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries"],"prefix":"10.1016","volume":"223","author":[{"given":"Natalia","family":"Echeverr\u00eda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela","family":"Betancour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiana","family":"G\u00e1mbaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6816-3699","authenticated-orcid":false,"given":"Nelia","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Chiodi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Boschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alvaro","family":"Fajardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mart\u00edn","family":"S\u00f3\u00f1ora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gonzalo","family":"Moratorio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Cristina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pilar","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.virusres.2016.07.008_bib0005","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/jvh.12051","article-title":"The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank","volume":"20","author":"Alves","year":"2013","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.virusres.2016.07.008_bib0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3851\/IMP2821","article-title":"Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C","volume":"20","author":"Applegate","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virusres.2016.07.008_bib0015","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1053\/bega.1999.0073","article-title":"Replication of the hepatitis C virus","volume":"14","author":"Bartenschlager","year":"2000","journal-title":"Bailliere\u2019s Best Pract. Res. Clin. Gastroenterol."},{"key":"10.1016\/j.virusres.2016.07.008_bib0020","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1038\/srep20310","article-title":"Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): mining the GenBank HCV genome data","volume":"6","author":"Chen","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.virusres.2016.07.008_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.virusres.2014.11.003","article-title":"Influence of amino acid variations in the NS3 NS4A and NS4B of HCV genotypes 1a, 1b, 3a, 3b and 6f on the response to pegylated interferon and ribavirin combination therapy","volume":"196","author":"Chusri","year":"2015","journal-title":"Virus Res."},{"key":"10.1016\/j.virusres.2016.07.008_bib0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s12985-015-0414-1","article-title":"Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naive patients with chronic hepatitis C","volume":"12","author":"Costantino","year":"2015","journal-title":"Virol. J."},{"key":"10.1016\/j.virusres.2016.07.008_bib0035","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1101\/gr.849004","article-title":"WebLogo: a sequence logo generator","volume":"14","author":"Crooks","year":"2004","journal-title":"Genome Res."},{"key":"10.1016\/j.virusres.2016.07.008_bib0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1128\/MMBR.05023-11","article-title":"Viral quasispecies evolution","volume":"76","author":"Domingo","year":"2012","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.virusres.2016.07.008_bib0045","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1128\/JCM.05842-11","article-title":"Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-na??ve infected individuals","volume":"50","author":"Fonseca-Coronado","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.virusres.2016.07.008_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","author":"Halfon","year":"2011","journal-title":"J. Hepatol"},{"key":"10.1016\/j.virusres.2016.07.008_bib0055","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.bbacli.2015.01.004","article-title":"No correspondence between resistance mutations in the HCV-NS3 protease at baseline and early telaprevir-based triple therapy","volume":"3","author":"Hoffmann","year":"2015","journal-title":"BBA Clin."},{"key":"10.1016\/j.virusres.2016.07.008_bib0060","doi-asserted-by":"crossref","DOI":"10.1002\/hep.1840360704","article-title":"Course and outcome of hepatitis C","author":"Hoofnagle","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2016.07.008_bib0065","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1371\/journal.pmed.0050158","article-title":"Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-na\u00efve populations and associate with reduced treatment efficacy","volume":"5","author":"Johnson","year":"2008","journal-title":"PLoS Med."},{"key":"10.1016\/j.virusres.2016.07.008_bib0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1471-2148-6-29","article-title":"Assessment of methods of amino acid matrix selection and their use on empirical data shows that ad hoc assumptions for choice of matrix are not justified","volume":"6","author":"Keane","year":"2006","journal-title":"BMC Evol. Biol."},{"key":"10.1016\/j.virusres.2016.07.008_bib0075","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1089\/aid.1992.8.1549","article-title":"Signature pattern analysis: a method for assessing viral sequence relatedness","volume":"8","author":"Korber","year":"1992","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virusres.2016.07.008_bib0080","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/bioinformatics\/bth485","article-title":"The Los Alamos hepatitis C sequence database","volume":"21","author":"Kuiken","year":"2005","journal-title":"Bioinformatics"},{"key":"10.1016\/j.virusres.2016.07.008_bib0085","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3851\/IMP2873","article-title":"Resistance mutations are rare among protease inhibitor treatment-naive hepatitis C genotype-1 patients with or without HIV coinfection","volume":"20","author":"Lisboa-Neto","year":"2015","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virusres.2016.07.008_bib0090","first-page":"1","article-title":"Evaluation for liver transplantation in adults: 2013 practice guideline by the AASLD and the american society of transplantation","author":"Martin","year":"2013","journal-title":"Am. Assoc. Study Liver Dis."},{"key":"10.1016\/j.virusres.2016.07.008_bib0095","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1089\/aid.1994.10.1479","article-title":"Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates","volume":"10","author":"N\u00e1jera","year":"1994","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"10.1016\/j.virusres.2016.07.008_bib0100","doi-asserted-by":"crossref","first-page":"e86413","DOI":"10.1371\/journal.pone.0086413","article-title":"HCV genotypes, characterization of mutations conferring drug resistance to protease inhibitors, and risk factors among blood donors in S\u00e3o Paulo, Brazil","volume":"9","author":"Nishiya","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2016.07.008_bib0105","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/1743-422X-9-245","article-title":"Naturally occurring mutations to HCV protease inhibitors in treatment-na\u00efve patients","volume":"9","author":"Paolucci","year":"2012","journal-title":"Virol. J."},{"key":"10.1016\/j.virusres.2016.07.008_bib0110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1097\/00001432-200312000-00012","article-title":"The nature of interferon-alpha resistance in hepatitis C virus infection","volume":"16","author":"Pawlotsky","year":"2003","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.virusres.2016.07.008_bib0115","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1590\/S0074-02762012000200016","article-title":"Genetic diversity of NS3 protease from Brazilian HCV isolates and possible implications for therapy with direct-acting antiviral drugs","volume":"107","author":"Peres-da-Silva","year":"2012","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.virusres.2016.07.008_bib0120","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm.3248","article-title":"Understanding the hepatitis C virus life cycle paves the way for highly effective therapies","volume":"19","author":"Scheel","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.virusres.2016.07.008_bib0125","doi-asserted-by":"crossref","first-page":"21052","DOI":"10.1073\/pnas.1110534108","article-title":"A macrocyclic HCV NS3\/4A protease inhibitor interacts with protease and helicase residues in the complex with its full-length target","volume":"108","author":"Schiering","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.virusres.2016.07.008_bib0130","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijantimicag.2015.04.011","article-title":"Previous failure of interferon-based therapy does not alter the frequency of HCV NS3 protease or NS5B polymerase inhibitor resistance-associated variants: longitudinal analysis in HCV\/HIV co-infected patients","volume":"46","author":"Sede","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.virusres.2016.07.008_bib0135","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s10822-010-9352-6","article-title":"Ligand docking and binding site analysis with PyMOL and Autodock\/Vina","volume":"24","author":"Seeliger","year":"2010","journal-title":"J. Comput. Aided. Mol. Des."},{"key":"10.1016\/j.virusres.2016.07.008_bib0140","doi-asserted-by":"crossref","DOI":"10.1099\/vir.0.80401-0","article-title":"Genetic diversity and evolution of hepatitis C virus \u2212 15 years on","author":"Simmonds","year":"2004","journal-title":"J. Gen. Virol"},{"key":"10.1016\/j.virusres.2016.07.008_bib0145","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.virusres.2016.07.008_bib0150","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1093\/molbev\/msr121","article-title":"MEGA5: Molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods","volume":"28","author":"Tamura","year":"2011","journal-title":"Mol. Biol. Evol."},{"key":"10.1016\/j.virusres.2016.07.008_bib0155","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1093\/nar\/22.22.4673","article-title":"CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice","volume":"22","author":"Thompson","year":"1994","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.virusres.2016.07.008_bib0160","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/jac\/dkr581","article-title":"Naturally occurring hepatitis C virus (HCV) NS3\/4A protease inhibitor resistance-related mutations in HCV genotype 1-infected subjects in Italy","volume":"67","author":"Vicenti","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.virusres.2016.07.008_bib0165","first-page":"n\/a","article-title":"NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-na\u00efve subjects","author":"Vidal","year":"2016","journal-title":"J. Viral Hepat."},{"key":"10.1016\/j.virusres.2016.07.008_bib0170","article-title":"Hepatitis C, fact sheet n(164 [WWW document]","author":"World Health Organization","year":"2015","journal-title":"Hepat. C."},{"key":"10.1016\/j.virusres.2016.07.008_bib0175","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jis761","article-title":"Antiviral resistance and the future landscape of hepatitis C virus infection therapy","author":"Wyles","year":"2013","journal-title":"J. Infect. Dis"},{"key":"10.1016\/j.virusres.2016.07.008_bib0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1590\/S0074-02762013000100002","article-title":"Variability and resistance mutations in the hepatitis C virus NS3 protease in patients not treated with protease inhibitors","volume":"108","author":"Zeminian","year":"2013","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.virusres.2016.07.008_bib0185","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.apsb.2015.09.008","article-title":"Direct anti-HCV agents","volume":"6","author":"Zhang","year":"2016","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.virusres.2016.07.008_bib0190","article-title":"Host APOBEC3G protein inhibits HCV replication through direct binding at NS3","volume":"10","author":"Zhu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.virusres.2016.07.008_bib0195","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1002\/jmv.24015","article-title":"Protease inhibitor resistance mutations in untreated Brazilian patients infected with HCV: novel insights about targeted genotyping approaches","volume":"86","author":"de Carvalho","year":"2014","journal-title":"J. Med. Virol."}],"container-title":["Virus Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170216304385?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168170216304385?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,10]],"date-time":"2018-09-10T06:50:22Z","timestamp":1536562222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168170216304385"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":39,"alternative-id":["S0168170216304385"],"URL":"https:\/\/doi.org\/10.1016\/j.virusres.2016.07.008","relation":{},"ISSN":["0168-1702"],"issn-type":[{"value":"0168-1702","type":"print"}],"subject":[],"published":{"date-parts":[[2016,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Naturally occurring NS3 resistance-associated variants in hepatitis C virus genotype 1: Their relevance for developing countries","name":"articletitle","label":"Article Title"},{"value":"Virus Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virusres.2016.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}